Potential use of taurine against pterygium formation.

Dear Editor: Pterygium is a fibrovascular lesion involving the ocular surface and is characterized by proliferation, inflammatory infiltration, fibrosis, angiogenesis, and extracellular matrix breakdown (Fig. 1). The mechanism of pterygium formation remains incompletely understood. Ultraviolet radiation possibly induces ocular surface changes, and in particular, affects stem cells in the corneoscleral limbus. Such changes may be further exacerbated by other environmental factors, such as infection with human papillomavirus or oxidative stress. At the molecular level, alterations in the expression of tumor suppressor genes such as p53, induction of matrix metalloproteinase (MMP), and alterations in the expression of various growth factors are observed. Several treatment modalities, primarily including surgical interventions, for pterygium are available. Because bare sclera excision is associated with a high recurrence rate, pterygium excision is often combined with conjunctival autograft transplantation or mitomycin C therapy, b radiation therapy, or other adjunctive therapies to reduce the recurrence rates. At present, however, there is no consensus regarding the ideal treatment for patients with this disease. On the other hand, it was shown that transforming growth factor-b (TGF-b) was involved in the regulation of many physiologic and pathophysiologic processes. The presence of activated fibroblasts in pterygium tissue is possibly attributable to the actions of TGF-b, given the overexpression of this growth factor in pterygium tissue as compared to that in normal conjunctiva, as previously reported. This would be a good opportunity to introduce new modalities, especially dietary factors that alter the identified genes, and expression of inflammatory and growth factors effective on pterygium formation. Taurine, a sulphur-containing amino acid that has been found to be naturally present in seafood and meat, may play an important role in several essential biologic processes such as development of the central nervous system and retina, membrane stabilization, and immunity. However, data

[1]  M. Namazi,et al.  Taurine: a novel preventer of neurofibroma growth? , 2009, Journal of alternative and complementary medicine.

[2]  D. Spandidos,et al.  Pathogenetic mechanisms and treatment options for ophthalmic pterygium: trends and perspectives (Review). , 2009, International journal of molecular medicine.

[3]  Yeon-Ah Lee,et al.  Taurine chloramine differentially inhibits matrix metalloproteinase 1 and 13 synthesis in interleukin-1β stimulated fibroblast-like synoviocytes , 2007, Arthritis research & therapy.

[4]  D. Tan,et al.  Current concepts and techniques in pterygium treatment , 2007, Current opinion in ophthalmology.

[5]  W. Heird Taurine in neonatal nutrition – revisited , 2004, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[6]  R. Casey,et al.  Taurine protects against PMN dysfunction and death in urine , 2004, Urological Research.

[7]  D. Wakefield,et al.  Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases , 2004, Progress in Retinal and Eye Research.

[8]  K. Bhoola,et al.  Genealogy, expression, and cellular function of transforming growth factor-beta. , 2003, Pharmacology & therapeutics.

[9]  T. Amemiya,et al.  Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-β and tumor necrosis factor-α in the pterygium , 1996 .

[10]  P. Mehta,et al.  Immunologic Consequences of Taurine Deficiency in Cats , 1990, Journal of leukocyte biology.

[11]  R. Gordon,et al.  Taurine protects hamster bronchioles from acute NO2-induced alterations. A histologic, ultrastructural, and freeze-fracture study. , 1986, The American journal of pathology.

[12]  D. Wakefield,et al.  The pathogenesis of pterygium: current concepts and their therapeutic implications. , 2008, The ocular surface.

[13]  E. Park,et al.  Taurine and Its Chloramine: Modulators of Immunity , 2004, Neurochemical Research.

[14]  T. Amemiya,et al.  Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. , 1996, Acta histochemica.

[15]  B. Kendler Taurine: an overview of its role in preventive medicine. , 1989, Preventive medicine.